Research Collaboration With U. of Manitoba Professor Adrian West

Mar 15, 2017

VANCOUVER, British Columbia – March 15, 2017 – Aspect Biosystems Ltd., a leader in the field of 3D bioprinting and tissue engineering, is pleased to announce a research collaboration with University of Manitoba Professor Adrian West. The research collaboration is supported by the Canada Foundation for Innovation’s (CFI) John R. Evans Leaders Fund (JELF). The CFI’s JELF is providing funding to cover budgeted costs for accessing Aspect’s bioprinting platform. 

“At Aspect, we are committed to forming strategic academic collaborations with world-class researchers to drive forward the development of impactful applications of our Lab-on-a-Printer™ platform technology,” said Tamer Mohamed, President and CEO of Aspect Biosystems. “We are particularly excited to work with Dr. West to expand the applications of our 3DBioRing™ muscle tissue platform and develop healthy and disease models of other tissues including blood vessels, skeletal and heart muscles. Ultimately, this collaboration will enable us to apply our Lab-on-a-Printer™ bioprinting technology to create novel tissues that can be used for the development of improved therapeutics for a host of vascular, cardiovascular, and respiratory diseases.”
“Three-dimensional bioprinting is the future of biomedical research and regenerative medicine, and Aspect Biosystems’ unique technology is at the forefront,” said Professor West. “By partnering with Aspect Biosystems and the Canada Foundation of Innovation to establish a tissue-engineering platform within my laboratory it will allow us to study the mechanisms that cause disease, and to test novel therapeutic strategies, with unprecedented speed and accuracy.”  

About Aspect Biosystems Ltd.

Aspect Biosystems Ltd. is a privately held biotechnology company operating at the leading edge of 3D bioprinting and tissue engineering. The company’s proprietary Lab-on-a-Printer™ platform technology is enabling advances in understanding fundamental biology, disease research, development of novel therapeutics, and regenerative medicine. In addition to its internal programs, Aspect is focused on strategically partnering with pharmaceutical and biotechnology companies, as well as academic researchers, to create physiologically and commercially relevant tissues. These tissues are used to advance and accelerate the discovery and development of new drugs and therapies.

Back to all